Risperidone, an atypical antipsychotic, is used to treat acute manic episodes, particularly when psychotic symptoms are present. Drugs used to treat mania are often continued as long-term treatment to prevent relapse. There is a need for evidence of the effectiveness and safety of risperidone as long-term treatment.
To assess the randomised evidence for the efficacy and tolerability of risperidone compared with placebo or other active pharmacological treatments as long-term treatment for prevention or attenuation of further episodes of mood disorder in patients with bipolar disorder.
The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR-Studies) was search on 12/10/2005, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, CINAHL and PsycINFO were searched in October 2005. Reference lists and English language textbooks were searched; researchers in the field were contacted.
Randomised trials comparing risperidone with placebo or other drug in long-term treatment for prevention of depressive or manic relapses.
Data collection and analysis
No randomised trials comparing risperidone with other treatments for the prevention of manic and depressive relapses were identified.
There is a need for randomised controlled trials comparing risperidone and other treatments for the prevention of relapse in bipolar disorder. The trials should involve randomisation of treatment for relapse prevention and involve long-term follow up.
Risperidone,一種非典型抗精神病藥物,被用來治療急性躁症發作特別是有精神症狀時. 藥物治療躁症通常持續為長期治療來防止復發. Risperidone在作為長期治療雙極性疾患上的效果和安全性的證據是必須的.
The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTRStudies)於12/10/2005被搜尋, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, CINAHL and PsycINFO於2005年十月被搜尋. 參考文獻列表與英文語文的教科書被搜尋;聯絡了這個領域的研究者.
此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。